“The therapy of idiopathic pulmonary fibrosis: what is next?” Vivien Somogyi, Nazia Chaudhuri, Sebastiano Emanuele Torrisi, et al. Eur Respir Rev 2019; 28: 190021.

Unfortunately, in this article in the September 2019 issue of the European Respiratory Review, the mechanism of action for PBI-4050 in table 2 was presented incorrectly as anti-CTGF antibody. The correct mechanism of action should be GPR84 antagonist/GPR40 agonist. The article has been corrected and republished online.